These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8731176)

  • 1. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
    Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
    Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.
    Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC
    Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
    Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
    Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
    Ford GA; Wood SM; Daly AK
    Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease.
    Saitoh T; Xia Y; Chen X; Masliah E; Galasko D; Shults C; Thal LJ; Hansen LA; Katzman R
    Ann Neurol; 1995 Jan; 37(1):110-2. PubMed ID: 7818242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
    Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Debrisoquine hydroxylase gene polymorphism in meningioma.
    Wundrack I; Meese E; Müllenbach R; Blin N
    Acta Neuropathol; 1994; 88(5):472-4. PubMed ID: 7847077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM; Atchison BA; Somogyi AA; Drummer OH
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract]   [Full Text] [Related]  

  • 13. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dinucleotide repeat polymorphism at the debrisoquine 4-hydroxylase (CYP2D) locus.
    Trofatter JA; Gusella JF; Haines JL
    Nucleic Acids Res; 1991 May; 19(10):2802. PubMed ID: 2041763
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
    Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
    Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
    [No Abstract]   [Full Text] [Related]  

  • 18. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
    Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
    Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 genes and risk of liver cancer.
    Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
    Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.
    Heim MH; Meyer UA
    Methods Enzymol; 1991; 206():173-83. PubMed ID: 1686063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.